Neurogene
Latest round
- Series B
Last raised
- Dec 2020
Total raised
- $138M
Investors
- 11
About Neurogene
Based in the US, Neurogene Inc.Founded in 2018 and headquartered in New York, Neurogene Inc. develops genetic medicines aimed at treating rare neurological diseases.00 mn on November 4, 2024.Neurogene focuses on developing innovative genetic medicines, particularly through its core product offering, the NGN-401 gene therapy candidate, which employs the proprietary EXACT™ technology. This technology is designed to regulate transgene expression, addressing the critical needs of patients with dosage-sensitive neurological disorders such as Rett syndrome. Neurogene aims to alleviate the burden of devastating neurological diseases by providing therapeutic options that have the potential to improve patient outcomes and quality of life. The primary end users of these genetic medicines are families affected by rare neurological conditions, and the company’s products are targeted towards healthcare providers and specialists in the field of genetic therapy.Neurogene generates revenue primarily through partnerships and collaborations within the biotechnology and pharmaceutical sectors, focusing on advancing its gene therapy programs. The business model is built around strategic alliances with research institutions and healthcare providers, facilitating clinical trials and the eventual commercialization of its gene therapy products. Transactions typically involve agreements for licensing and co-development, enabling Neurogene to capitalize on its innovative technologies while sharing development costs and risks. Pricing structures for its therapies are determined as part of these collaborations, with the flagship NGN-401 potentially entering pricing negotiations based on clinical data and therapeutic value upon regulatory approval.In November 2024, Neurogene Inc. Additionally, the company aims to expand into new markets, specifically targeting regions in North America and Europe by leveraging its innovative gene therapies to meet the unmet medical needs in these areas.
Who invested in Neurogene
11 investors across 2 rounds
See all investors in Neurogene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Neurogene
Who invested in Neurogene?
Neurogene has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neurogene raised?
Neurogene has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Neurogene last raise money?
Neurogene's most recent round on record is a Series B, in Dec 2020.
What does Neurogene do?
Based in the US, Neurogene Inc.
Where is Neurogene headquartered?
Neurogene is headquartered in New York, US.
Which VCs invest in companies like Neurogene?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Neurogene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Neurogene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.